GD2 chimeric antigen receptor-expressing peripheral blood T cells(R…

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 16 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Not Applicable

Clinical phase

Suspended

Recruitment status

not reported

Planned enrollment

Timing not reported

Primary-completion proxy

Executive view

ACTRN12622001514796 evaluates GD2 chimeric antigen receptor-expressing peripheral blood T cells(Royal Adelaide Hospital) in Astrocytoma. The disclosed sponsor is Royal Adelaide Hospital, the design is Interventional, and the geographic footprint is Australia. The first listed primary endpoint is not reported, assessed over an unreported time frame.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for ACTRN12622001514796 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Astrocytoma landscape. Drug & Asset MCP drug_fetch was queried for GD2 chimeric antigen receptor-expressing peripheral blood T cells(Royal Adelaide Hospital), while Company & Deal Intelligence MCP organization_fetch was queried for Royal Adelaide Hospital.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
ACTRN12622001514796	GD2 chimeric antigen receptor-expressing peripheral blood T cells(Royal Adelaide Hospital)	Not Applicable / Suspended	Royal Adelaide Hospital	Australia		Timing not reported
ACTRN12623000956606	AT-0174	Phase 1 / Recruiting	Antido Therapeutics (Australia) Pty Ltd	Australia		Timing not reported
NCT06018363	QH104	Phase 1/2 / Recruiting	The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital)	China	Phase 1: Incidence of Adverse Events (AEs) 12 months	2027-12-31
NCT06016452	Chlorophyllin Copper Sodium	Phase 2 / Recruiting	Tata Memorial Centre	India	Response rates 1 month post treatment with chlorophyllin	2025-11-01
NCT06011109	APG-157	Phase 1/2 / Active, not recruiting	Aveta Biomics, Inc.	United States	Progression-free Survival From date of commencement of treatment until the date of first docume…	2026-12-31

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

ACTRN12622001514796 is a Not Applicable, suspended study with not reported planned participants. Allocation is Non-randomised trial, masking is Open (masking not used), and the intervention model is not reported.

The primary endpoint is “not reported” over “not reported.” The retrieved endpoint description is: To establish the feasibility of preparing GD2-specific chimeric antigen receptor (CAR) T cells at the time of diagnosis of recurrent glioblastoma multiforme (rGBM) for intravenous administration at the time of recurrence. Measured by T-cell products generated, participant blood collection and urine collection.[ GD2-iCAR-PBT generation for this trial takes approximately 3 weeks];To determine the safety profile and dose limiting toxicities of intravenous administration of GD2-CAR T cells in patients with rGBM. Measured by medical review of adverse event reports and the results of vital sign measurements (Blood pre….

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

0 recent result records were selected as contextual evidence for Astrocytoma. These records do not establish direct evidence for ACTRN12622001514796 unless the registration number matches.

Indexed evidence status

No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

GD2 chimeric antigen receptor-expressing peripheral blood T cells(Royal Adelaide Hospital) is indexed as Autologous CAR-T with GD2 biology and a global stage of Phase 1. The asset profile lists Royal Adelaide Hospital as an originator or developer.

Royal Adelaide Hospital is indexed in an unreported country with the website http://www.rah.sa.gov.au/homepage.php. Royal Adelaide Hospital provides a health care system. The record lists 1 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether GD2 chimeric antigen receptor-expressing peripheral blood T cells(Royal Adelaide Hospital) is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: ACTRN12622001514796
Protocol source: https://anzctr.org.au/ACTRN12622001514796.aspx
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 October 2026.

GD2 chimeric antigen receptor-expressing peripheral blood T cells(Royal Adelaide Hospital) in Astrocytoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes the primary endpoint and Timing not reported the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP